Industry News (Joint Venture)

Collaboration Announced To Investigate Anticode Oligonucleotides

Published in Cancer Weekly, October 16th, 1995

Genta Inc., San Diego, California, announced that it has signed an agreement for a limited feasibility study with Baxter Healthcare Corp., Deerfield, Illinois, to investigate the ability of certain anticode oligonucleotides to promote the death of mature human T cells.

The feasibility study, which is divided into three phases, calls for Baxter to fully fund, in advance, the first phase and, subject to satisfactory test results and continued interest by Baxter, the second and/or third phases. Phase three would be preceded by the execution of a mutually satisfactory license and supply agreement.

Genta and Baxter believe that inducing mature T cells...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry